Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice-Reference-Cited by-同舟云学术

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Published:2022-06-11 Issue:9 Volume:52 Page:773-783
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Tanaka Takaaki¹,Hiraoka Atsushi¹^ORCID,Tada Toshifumi²^ORCID,Hirooka Masashi³,Kariyama Kazuya⁴^ORCID,Tani Joji⁵,Atsukawa Masanori⁶,Takaguchi Koichi⁷,Itobayashi Ei⁸,Fukunishi Shinya⁹,Tsuji Kunihiko¹⁰,Ishikawa Toru¹¹,Tajiri Kazuto¹²^ORCID,Ochi Hironori¹³,Yasuda Satoshi¹⁴,Toyoda Hidenori¹⁴^ORCID,Ogawa Chikara¹⁵,Nishimura Takashi¹⁶,Hatanaka Takeshi¹⁷,Kakizaki Satoru¹⁸^ORCID,Shimada Noritomo¹⁹,Kawata Kazuhito²⁰^ORCID,Naganuma Atsushi²¹,Kosaka Hisashi²²,Ohama Hideko⁹,Nouso Kazuhiro⁴^ORCID,Morishita Asahiro⁵^ORCID,Tsutsui Akemi⁷,Nagano Takuya⁷,Itokawa Norio⁶,Okubo Tomomi⁶,Arai Taeang⁶,Imai Michitaka¹¹,Koizumi Yohei³,Nakamura Shinichiro²,Joko Kouji¹³^ORCID,Iijima Hiroko¹⁶,Kaibori Masaki²²,Hiasa Yoichi³^ORCID,Kudo Masatoshi²³,Kumada Takashi²⁴^ORCID, ,

Affiliation:

1. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

2. Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan

3. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Toon Japan

4. Department of Hepatology Okayama City Hospital Okayama Japan

5. Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan

6. Division of Gastroenterology and Hepatology Department of Internal Medicine Nippon Medical School Tokyo Japan

7. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

8. Department of Gastroenterology Asahi General Hospital Asahi Japan

9. Department of Gastroenterology Osaka Medical and Pharmaceutical University Osaka Japan

10. Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan

11. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

12. Department of Gastroenterology Toyama University Hospital Toyama Japan

13. Hepato‐biliary Center Japanese Red Cross Matsuyama Hospital Matsuyama Japan

14. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan

15. Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Japan

16. Department of Gastroenterology and Hepatology Hyogo College of Medicine Nishinomiya Japan

17. Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Gunma Japan

18. Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan

19. Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

20. Hepatology Division Department of Internal Medicine II Hamamatsu University School of Medicine Hamamatsu Japan

21. Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki Japan

22. Department of Surgery Kansai Medical University Hirakata Japan

23. Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan

24. Department of Nursing Gifu Kyoritsu University Ogaki Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13797

Reference49 articles.

1. Estimating the world cancer burden: Globocan 2000

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma;Oncology;2024-07-30

2. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC;Clinical Gastroenterology and Hepatology;2024-07

3. Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study;Liver Cancer;2024-06-14

4. Efficacy and Safety of Transarterial Chemoembolization Combined with PD-1 Inhibitors plus Molecular Targeted Therapies for Unresectable Hepatocellular Carcinoma with Child‒Pugh B;2024-05-28

5. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial;Alimentary Pharmacology & Therapeutics;2024-05-08